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Abstract Background
We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared findings with recent trials of pharmacological inhibitors of PCSK9.
Methods
Published and individual participant level data (300,000+ participants) were combined to construct a weighted PCSK9 gene-centric score (GS). Fourteen randomized placebo controlled PCSK9 inhibitor trials were included, providing data on 79,578 participants. Results were scaled to a one mmol/L lower LDL-C concentration Results The PCSK9 GS (comprising 4 SNPs) associations with plasma lipid and apolipoprotein levels were consistent in direction with treatment effects. The GS odds ratio (OR) for myocardial infarction (MI) was 0.53 (95%CI 0.42; 0.68), compared to a PCSK9 inhibitor effect of 0.90 (95%CI 0.86; 0.93). For ischemic stroke ORs were 0.84 (95%CI 0.57; 1.22) for the GS, compared to 0.85 (95%CI 0.78; 0.93) in the drug trials. ORs with type 2 diabetes mellitus (T2DM) were 1.29 (95% CI 1.11; 1.50) for the GS, as compared to 1.00 (95%CI 0.96; 1.04) for incident T2DM in PCSK9 inhibitor trials. No genetic associations were observed for cancer, heart failure, atrial fibrillation, chronic obstructive pulmonary disease, or Alzheimer's disease -outcomes for which large-scale trial data were unavailable.
Conclusions Genetic variation at the PCSK9 locus recapitulates the effects of therapeutic inhibition of PCSK9 on major blood lipid fractions and MI. Apparent discordance between genetic associations and trial outcome for T2DM might be explained lack by a of statistical precision, or differences in the nature and duration of genetic versus pharmacological perturbation of PCSK9. 
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Condensed abstract
Evidence on the long-term efficacy and safety of therapeutic inhibition of PCSK9 is lacking.
To explore potential long-term effects of PCSK9 inhibition, we characterised the phenotypic consequence of LDL-cholesterol lowering variants at the PCSK9 locus. A PCSK9 gene score comprising 4 SNPs recapitulated the effects of therapeutic inhibition of PCSK9 on major blood lipid fractions and risk of myocardial infarction, and was associated with an increased risk of type 2 diabetes. No associations with safety outcomes such as cancer, COPD, Alzheimer's disease or atrial fibrillation were identified. Our findings suggest PCSK9 inhibition may be safe and effective during prolonged use.
Introduction
Statins and ezetimibe reduce the risk of major coronary events and ischemic stroke via lowering of low density lipoprotein-cholesterol (LDL-C) (1) (2) (3) . Loss-of-function mutations in PCSK9 are associated with lower LDL-C and a reduced risk of coronary heart disease (CHD) (4, 5) . Antibodies (mAbs) inhibiting PCSK9, reduce LDL-C in patients with hypercholesterolaemia, and received market access in 2015.The FOURIER and ODYSSEY OUTCOMES trials tested the efficacy of PCSK9-inhibition versus placebo on the background of statin treatment and both found that PCSK9 inhibition led to a 15% relative risk reduction of major vascular events in patients with established CVD and recent acute coronary syndrome over a median follow up of 2.2 or 2.8 years (6, 7) .
Evidence is limited on the effect of PCSK9 inhibition on clinical outcomes, and on safety outcomes that might only become apparent with prolonged use. Nor is evidence available on the efficacy and safety of PCSK9 inhibitors in subjects other than the high-risk patients studied in trials. Mendelian randomisation for target validation uses naturally-occurring variation in a gene encoding a drug target to identify mechanism-based consequences of pharmacological modification of the same target (8) . Such studies have previously proved useful in predicting success and failure in clinical trials and have assisted in delineating ontarget from off-target actions of first-in-class drugs (9) (10) (11) (12) (13) . For example, previous studies showed that variants in HMGCR, encoding the target for statins, were associated with lowering concentrations of LDL-C and lower risk of coronary heart disease(9) (CHD), while confirming the on-target nature of the effect of statins on higher body weight and higher risk of type 2 diabetes (T2DM) (9) .
We characterised the phenotypic consequences of genetic variation at PCSK9 in a large, general population sample focussing on therapeutically relevant biomarkers, cardiovascular disease (CVD), individual CVD components and non-CVD outcomes such as cancer, Alzheimer's disease, and chronic obstructive pulmonary disease (COPD). Effect estimates from the genetic analysis were compared to those from intervention trials where the outcomes under evaluation overlapped.
Methods
We summarise methods briefly here as they have been previously described in detail (14) . 
Genetic variant selection

Individual participant-level and summary-level data
Participating studies (Appendix table 2 We focussed on individual clinical endpoints, rather than composites, which have been assessed in outcome trials, as well as disease end-points commonly seen in patients likely to be eligible for PCSK9 inhibitor treatment. Ischemic CVD endpoints studied were myocardial infarction (MI), ischemic stroke, revascularization, and angina. The following non-ischemic CVD events were considered: haemorrhagic stroke, heart failure, and atrial fibrillation. Non-CVD outcome data was collected on common chronic diseases: COPD, any cancer (including those of the breast, prostate, colon and lung), Alzheimer's disease, and T2DM.
Finally, aggregated trial data on the effect of monoclonal PCSK9 inhibitors were compared to placebo for MI, revascularization, ischemic or haemorrhagic stroke, cancer, and T2DM abstracted from the Cochrane systematic review (6) . We compared effects on biomarkers and clinical endpoints common to both the genetic analysis and trials.
Statistical analyses
In all analyses, we assumed an additive allele effect with genotypes coded as 0, 1 and 2, corresponding to the number of LDL-C lowering alleles. Continuous biomarkers were analysed using linear regression and binary endpoints using logistic regression. Studyspecific associations were pooled for each SNP using the inverse variance weighted method for fixed effect meta-analysis. Study-specific associations were excluded if the SNP was not in Hardy-Weinberg equilibrium (see Appendix Table 4 , based on a Holm-Bonferroni alpha criterion). We estimated the effect at the PCSK9 locus by combining all four SNPs in a gene centric score (GS).
Trial data were assembled as per Schmidt et al. 2017 (6) . Briefly, systematic searches were performed using the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Web of Science registries, Clinicaltrials.gov and the International Clinical Trials Registry Platform databases. Data from placebo controlled trials were extracted and combined using the inverse variance weighted method for continuous data and a random-intercept logistic regression model for binary data (6) .
Results are presented as mean differences (MD) or odds ratios (OR) with 95% confidence intervals (CI). Analyses were conducted using the statistical programme R version 3.4.1 (16) .
Role of the funding source
The funder(s) of the study played no role in study design, data collection, data analysis, data interpretation, or writing of the report. AFS had full access to all the data in the study and shares final responsibility for the decision to submit for publication with all authors.
Local ethics committees for studies contributing data to these analyses granted approval for the work.
Results
Participant level data were available from up to 246,355 individuals, and were supplemented by summary effect estimates from data repositories, resulting in a sample size of 320,170 individuals, including 95,865 cases of MI, 16,437 stroke, 11,920 ischemic stroke, 51,623 T2DM, 54,702 cancer, 25,630 Alzheimer's disease and 12,412 of COPD.
Lipid and apolipoprotein associations
As reported previously (14) , the four PCSK9 SNPs were associated with lower LDL-C blood concentrations ranging from -0.02 mmol/L (95%CI -0.03; -0.02) per allele for rs11583680 to -0.34 mmol/L (95%CI -0.36; -0.32) for rs11591147 (See Appendix Figure 1 ). PCSK9 SNPs associated with a lower LDL-C concentration were also associated with lower concentrations of apolipoprotein B proportionate to the LDL-C association.
Associations of the GS with the other lipids or apolipoproteins, scaled to a 1 mmol/L lower LDL-C were ( Table 1) The associations of the PCSK9 GS with blood-based lipid markers were directionally concordant with effects from treatment trials of therapeutic inhibition of PCSK9 (Figure 1 ).
Genetic associations with other biochemical and physiological measures
The GS estimates with SBP and DBP were 0.03 mmHg (95%CI -0.05; 0.10) and 0.08 mmHg (95%CI 0.0001; 0.15), respectively, per 1 mmol/L lower LDL-C. The PCSK9 GS was associated with nominally lower ALP (IU/L) -0.06 (95%CI -0.09; -0.02), but not with other liver enzymes (Table 1) .
Genetic associations with ischemic cardiovascular events
The PCSK9 GS was associated with a lower risk of MI (OR 0.53; 95%CI 0.42; 0.68; 95,865 cases), which was directionally consistent with results from placebo-controlled PCSK9 inhibition trials: OR 0.90 (95%CI 0.86; 0.93), with both estimates scaled to a 1 mmol/L lower LDL-C (Figures 2 and 3 (Figure 3 ).
Genetic associations with non-ischemic cardiovascular disease
The point estimate for the GS association with hemorrhagic stroke (Figure 2 ), OR 1.29 (95%CI 0.76; 2.19), was discordant to the estimate from PCSK9 inhibitor trials (OR 0.96 95%CI 0.75; 1.23) (Figure 3 ), although the confidence intervals overlapped. Comparing the association of PCSK9 GS with hemorrhagic and ischemic stroke indicated the GS had a differential effect (p-value = 0.02). No PCSK9 GS association was observed with atrial fibrillation (OR 0.92 95%CI 0.72; 1.18; 41 485 cases), or heart failure (OR 1.06 95%CI 0.88; 1.28; 23,763 cases) ( Figure 2 ).
Associations with non-cardiovascular disease and related biomarkers
The PCSK9 GS was not associated with the risk of any cancer (OR 0.97: 95%CI 0.81; 1.17; 54,702 cases, see Figure 4 ), nor with any of 13 specific types of cancer (Appendix Figure 2 ).
We did not observe an association with either Alzheimer's disease or cognitive performance:
for Alzheimer's the OR was 0.91 (95%CI 0.55; 1.51) and for cognition (per standard deviation) -0.03 (95%CI -0.22; 0.16). As reported before (14) the GS was associated with T2DM (OR 1.00 95%CI 1.11; 1.50) (Figure 4 ), higher body weight (1.03 kg; 95%CI 0.24; 1.82), waist to hip ratio 0.006 (95%CI 0.003; 0.011) and fasting glucose 0.09 mmol/L (95%CI 0.02; 0.15). The OR for COPD was 0.89 (95%CI 0.67; 1.18).
Discussion
The genetic findings presented here show that variation in PCSK9 is associated with lower circulating LDL-C and apoB concentrations, lower risk of MI and, with lesser confidence, the risk of ischemic stroke and coronary revascularization. These effects are consistent in direction to effects observed in the first PCSK9 inhibitor trial's (17) .
A recent systematic review of trial data(18) indicated a potential dysglycaemic effect from PCSK9 inhibition. PCSK9 monoclonal antibodies were associated with increased fasting glucose (0.17 as standardized mean difference [SMD] 95%CI 0.14; 0.19) and glycosylated haemoglobin (0.10 SMD 95%CI 0.07; 0.12) (18) . Recently we, and others, showed natural genetic variation PCSK9 was associated with elevated fasting glucose and T2DM (14, 19, 20) and that variation at other LDL-C-associated loci also influence risk of T2DM (21, 22) . (24) . We selected a subset of all genetic variants at PCSK9 that capture information on many others and which have some annotated function. However, other approaches to more fully capture the entire gene-centric effect are worthy of future investigation (25) .
The association of PCSK9 variants with LDL-C and MI has been reported before (5) , and was a motivating factor for the development of PCSK9 inhibiting drugs. Lotta and colleagues (19) reported a similar OR for MI of 0.60 (95%CI 0.48; 0.75) per 1 mmol/L decrease in LDL-C using the PCSK9 rs11591147 SNP. Using a seven SNP PCSK9 GS, Ference et al. reported a MI OR of 0.44 (95%CI 0.31; 0.64) per 1 mmol/L decrease in LDL-C (20) . These scaled genetic effects are larger than the treatment effect observed in trials which others have noted previously (26) , and ascribed to the lifelong effect of genetic variation versus the short-term effect of drug treatment in later life.
The available trial data showed PCSK9 inhibitors had a similar effect on MI (OR 0.90, 95%CI 0.86; 0.93) and ischemic stroke (OR 0.85 95%CI 0.78; 0.93). By contrast, the genetic analysis indicated a directionally concordant, but larger effect on MI (OR 0.53; 95%CI 0.42; 0.68) than ischemic stroke, (OR 0.84 95%CI 0.57; 1.22). The genetic analysis was, however, based on only 11,920 stroke cases, about one-fifth of the number of cases available for the genetic analysis of MI and as such confidence interval overlapped. We did observe a significantly differential association between PCKS9 SNPs and ischemic and hemorrhagic stroke (interaction p-value = 0.02). Findings from statin trials previously suggested LDL-C lowering through inhibition of HMG-coA reductase is associated with a reduced risk of ischemic but potentially increased risk of hemorrhagic stroke (27) (28) (29) . Our findings suggest that a different effect on ischemic and hemorrhagic stroke subtypes may be eventually identified for PCSK9 inhibitors.
Despite previous concerns about a potential effect of this class of drugs on cognition (30) , the genetic analysis did not reveal a significant association of the four PCSK9 variants with cognitive function or Alzheimer's disease, nor with COPD or cancer, though this does not preclude an effect on such outcomes from drug treatment given in later life. While we explored the associations with any cancer (54702 events) as well as 12 individual cancer sites (Appendix Figure 2) , we did not have data on some clinically relevant cancer types such as endometrial cancer.
This neutral effect on cognition has been recently reported by the EBBINGHAUS study, Drugs (even apparently specific monoclonal antibodies) can exert actions on more than one protein if such targets belong to a family of structurally similar proteins. PCSK9, for example, is one of nine related proprotein convertases (32) . Such 'off-target' actions, whether beneficial or deleterious, would not be shared by variants in the gene encoding the target of interest. In addition, monoclonal antibodies clear circulating PCSK9 from the blood and should not, in theory, influence any intracellular action of the protein (33) .
Genetic association studies of the type conducted here tend to examine the risk of a first clinical event, whereas clinical trials such as ODYSSEY OUTCOMES focus on patients with established disease, where mechanisms may be modified. Proteins influencing the risk of a first event may also influence the risk of subsequent events, as observed in the case of the target of statin drugs that are effective in both primary and secondary prevention (1) . For this and other reasons (34) (35) (36) , examination of the effects of PCSK9 variants on the risk of subsequent CHD events in patients with established coronary atherosclerosis is the subject of a separate analysis led by the GENIUS-CHD consortium (36) .
In conclusion, PCSK9 SNPs associated with lower LDL-C predict a substantial reduction in the risk of MI and concordant associations with a reduction in risk of ischemic stroke, but with a modestly increased risk of T2DM. We did not observe significant associations with other non-cardiovascular safety outcomes such as cancer, COPD, Alzheimer's disease or atrial fibrillation. These findings suggest that it is likely that PCSK9 inhibitor therapy will not have any clinically meaningful effect on non-vascular diseases but it may increase risk of T2DM.
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